Please assess the completion status of the following clinical trial:

Trial Title: A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed primary hepatocellular carcinoma (HCC)~* Inoperable disease (T2-T4, any N, M0 or M1) or refused surgery~* Measurable disease~* At least 1 bidimensionally measurable lesion of at least 2 cm by computed tomography (CT) scan or magnetic resonance imaging (MRI)~* Presence of at least 1 of the following:~* Alpha-fetoprotein greater than the upper limit of normal (ULN)~* Hepatitis C antibody positive~* Hepatitis B surface antigen positive~* Child's Pugh class A or B~* Candidate for systemic therapy~Exclusion Criteria:~* Fibrolamellar disease mixed histology~* Metastatic brain or meningeal tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib 400 mg b.i.d. (Type: EXPERIMENTAL): Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)

Based on this trial design, predict the completion outcome and termination type (if applicable).